188RE-SSS Lipiodol to Treat HepatoCellular Carcinomas
Status:
Completed
Trial end date:
2019-08-06
Target enrollment:
Participant gender:
Summary
This study is to determine the maximum tolerated dose and the recommended 188Re-SSS Lipiodol
activity for hepatic intra-arterial injection in patients with hepato-cellular carcinoma. The
new radioactive isotope 188Rhenium associated with Lipiodol is expected to reduce the
radioprotection constraints and hence the duration of the hospitalisation in a protected room
from 8 to 1 day.
Phase:
Phase 1
Details
Lead Sponsor:
Center Eugene Marquis
Collaborators:
Ecole Nationale Superieure de Chimie de Rennes Rennes University Hospital